Beyond Beta-Amyloid - Deciphering Early Pathogenic Changes in Alzheimer's disease

Funder

Organizational Unit

Publications

Memory awareness in patients with major depressive disorder

Publication . Mendes, Tiago; Cardoso, Sandra; Guerreiro, Manuela; Marôco, João Paulo.; Silva, Dina; Alves, Luísa; Schmand, Ben; Couto, Frederico Simões Do; Figueira, Maria Luísa; De Mendonça, Alexandre

Subjective Memory Complaints (SMC) along with cognitive deficits are frequently observed in patients with Major Depressive Disorder (MDD). The relationship between SMC and objective memory performance in patients with MDD was evaluated, in comparison with patients with Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD) and healthy controls (HC).

2021Journal article

Open access

Neuropsychological contribution to predict conversion to dementia in patients withmild cognitive impairment due Alzheimer’s disease

Publication . Silva, Dina Lúcia Gomes da; Cardoso, Sandra; Guerreiro, Manuela; Marôco, J. P.; Mendes, Tiago; Alves, Luísa; Nogueira, Joana Maia; Baldeiras, Ines; Santana, Isabel; Mendonça, Alexandre de

Diagnosis of Alzheimer's disease (AD) confirmed by biomarkers allows the patient to make important life decisions. However, doubt about the fleetness of symptoms progression and future cognitive decline remains. Neuropsychological measures were extensively studied in prediction of time to conversion to dementia for mild cognitive impairment (MCI) patients in the absence of biomarker information. Similar neuropsychological measures might also be useful to predict the progression to dementia in patients with MCI due to AD.

2020Journal article

Restricted access

Neuropsychological profile of amyloid-positive versus amyloid-negative amnestic Mild Cognitive Impairment

Publication . Alves, Luísa; Cardoso, Sandra; Silva, Dina; Mendes, Tiago; Maroco, J. P.; Nogueira, Joana; Lima, Marisa; Pereira, Miguel Tábuas; Baldeiras, Inês; Santana, Isabel; De Mendonça, Alexandre; Guerreiro, Manuela

Patients diagnosed with amnestic mild cognitive impairment (aMCI) are at high risk of progressing to dementia. It became possible, through the use of biomarkers, to diagnose those patients with aMCI who have Alzheimer's disease. However, it is presently unfeasible that all patients undergo biomarker testing. Since neuropsychological testing is required to make a formal diagnosis of aMCI, it would be interesting if it could be used to predict the amyloid status of patients with aMCI.

2020-06-26Journal article

Open access